Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial

Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been used increasingly as an anticoagulant during continuous renal replacement therapy (CRRT). However, there, are limited data from randomized studies on NM use in patients with a bleeding tendency. This prospective study evaluate...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Medicine (Baltimore)
Main Authors: Choi, Ji-Young, Kang, Yun-Jeong, Jang, Hye Min, Jung, Hee-Yeon, Cho, Jang-Hee, Park, Sun-Hee, Kim, Yong-Lim, Kim, Chan-Duck
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer Health 2015
Teme:
5200
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5291631/
https://ncbi.nlm.nih.gov/pubmed/26717390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000002392
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki